Alteplase is a serine protease that binds to fibrin in a thrombus or blood clot resulting in
conversion of plasminogen to plasmin and initiation of local fibrinolysis. Alteplase has been …

Alteplase (Activase), a clot-busting drug routinely given to heart attack patients, is safe and
effective for treating stroke and can reduce disability if it is given to patients quickly, scientists …

The results of the National Institute of Neurological Diseases and Stroke (NINDS) trial
represent a real breakthrough, demonstrating that thrombolytic therapy with intravenous …

Background: Intravenous recombinant tissue plasminogen activator (tPA, alteplase) was
conditionally licensed for the treatment of acute ischemic stroke (AIS) in Canada on …

Abstract Alteplase (Actilyse®, Activase®) is a recombinant tissue-type plasminogen activator
that activates plasminogen directly to plasmin. It is the only pharmacological treatment …

Thrombolytic therapy with alteplase (tPA; Activase (®)) has been approved in the US and
Canada for use in the treatment of acute ischemic stroke (AIS). Based on the results of five …

Boehringer Ingelheim has announced preliminary findings from the European Cooperative
Acute Stroke Study II (ECASS II) evaluating alteplase in stroke patients. The study showed …

The onset of alteplase therapy within 90 minutes after the onset of acute ischaemic stroke
significantly improves the likelihood of favourable outcomes at 24 hours and 3 months post …

SESLHDPR/236 - Alteplase (Recombinant Tissue Plasminogen Activator) in Adult Acute
Ischaemic Stroke – Management of Page 1 SESLHD PROCEDURE COVER SHEET …

Ischemic stroke ranks as one of the major leading cause of death and the most common
cause of acquired neurological disability in adults. The treatment of acute ischemic stroke …